Research analysts at StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN – Get Free Report) in a research note issued on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Trevena in a report on Tuesday, April 2nd.
Check Out Our Latest Stock Report on Trevena
Trevena Price Performance
Hedge Funds Weigh In On Trevena
An institutional investor recently bought a new position in Trevena stock. Armistice Capital LLC purchased a new stake in Trevena, Inc. (NASDAQ:TRVN – Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned about 4.61% of Trevena as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 13.56% of the company’s stock.
Trevena Company Profile
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
Featured Articles
- Five stocks we like better than Trevena
- 3 Fintech Stocks With Good 2021 Prospects
- Charles Schwab Fortifies its Uptrend on EPS Beat
- Investing in Construction Stocks
- Lockheed Martin Stock Aims for a Fresh All-Time High
- Which Wall Street Analysts are the Most Accurate?
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.